Hepatitis C micro-elimination among people on opioid agonist therapy is a low-hanging fruit

Philip Bruggmann; Bettina Maeschli

doi:10.4414/smw.2020.20348

Viewpoint

Vol. 150 No. 3738 (2020)

Hepatitis C micro-elimination among people on opioid agonist therapy is a low-hanging fruit

Philip Bruggmann⁺⁻
Bettina Maeschli⁺⁻

DOI: https://doi.org/10.4414/smw.2020.20348
Cite this as:: Swiss Med Wkly. 2020;150:w20348
Published: 18.09.2020

References

Keiser O, Giudici F, Müllhaupt B, Junker C, Dufour JF, Moradpour D, et al.; Swiss Hepatitis C Cohort Study and the Swiss National Cohort. Trends in hepatitis C-related mortality in Switzerland. J Viral Hepat. 2018;25(2):152–60. doi:.https://doi.org/10.1111/jvh.12803
Schürch S, Fux C, Dehler S, Conen A, Knuchel J, Friedl A, et al. Management of hepatitis C in opioid agonist therapy patients of the Swiss canton Aargau within and outside the cohort study. Swiss Med Wkly. 2020.;150:w20317. doi:. https://doi.org/10.4414/smw.2020.20317
Beck T, Bruggmann P, Haemmig R, Caflisch C, Falcato L, Fink A, et al. Medizinische Empfehlungen für Opioidagonistentherapie (OAT) bei Opioidabhängigkeits-Syndrom 2020. Bern: SSAM; 2020.
Federal Office of Public Health Switzerland. Hepatitis C bei Drogenkonsumierenden. Richtlinien mit settingsspezifischen Factsheets. Bern: 2019. https://www.infodrog.ch/files/content/hepc_de/richtlinien-hepatitis-c-drogen-de-2019.pdf
Kind J, Maeschli B, Bruggmann P. Im Schatten von HIV: Das “Aschenbrödel” Hepatitis C. Suchtmedizin. 2019;21(3):103–10.
Müller D, Dittli J, Eder J, Ettlin E, Janiak C, Stöckli H. Motion 19.3743: Die Eliminierung von Hepatitis gehört in ein Nationales Programm sexuell und blutübertragbarer Infektionskrankheiten. In: EDI, editor. Bern: Die Bundesversammlung - das Schweizer Parlement; 2019.
Hepatitis Schweiz. The HepCare Project: Swiss Hepatitis; 2020: www.hepcare.ch.

Publication image

How to Cite

1.

Bruggmann P, Maeschli B. Hepatitis C micro-elimination among people on opioid agonist therapy is a low-hanging fruit. Swiss Med Wkly [Internet]. 2020 Sep. 18 [cited 2024 Nov. 19];150(3738):w20348. Available from: https://smw.ch/index.php/smw/article/view/2868

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Most read articles by the same author(s)

Francesco Negro, Beat Müllhaupt, David Semela, Sarah Blach, Philip Bruggmann, Andrea De Gottardi, Jean-Francois Dufour, Montserrat Fraga, Antonio Galante, Homie Razavi, Joana Vieira Barbosa, Devin Razavi-Shearer, The current and future burden of hepatitis B in Switzerland: a modelling study , Swiss Medical Weekly: Vol. 153 No. 6 (2023)
Muriel Kruijver, Philip Bruggmann, Raphael Magnolini, Evidence of use and users of image- and performance-enhancing drugs in sports in Switzerland: a scoping literature review and implications for Swiss drug policy , Swiss Medical Weekly: Vol. 153 No. 5 (2023)
Rosario Agosti-Gonzalez, Luis Falcato, Thomas Grischott, Oliver Senn, Philip Bruggmann, Hepatitis C antibody test frequencies and positive rates in Switzerland from 2007 to 2017: a retrospective longitudinal study , Swiss Medical Weekly: Vol. 153 No. 6 (2023)
Babette L. Winter, Frédérique Hovaguimian, Roger D. Kouyos, Axel Jeremias Schmidt, Enos Bernasconi, Dominique L. Braun, Alexandra Calmy, Julia Notter, Marcel Stoeckle, Bernard Surial, Vanessa Christinet, Matthias Cavassini, Carsten Depmeier, Severin Läuchli, Emmanuelle Boffi El Amari, Matthias Reinacher, Manuela Rasi, Philip Bruggmann, David Haerry, Raphaël Bize, Nicola Low, Andreas Lehner, Boris B. Quednow, Jan S. Fehr, Benjamin Hampel, Changes in mental and sexual health among MSM using HIV pre-exposure prophylaxis during the SARS-CoV-2 pandemic: longitudinal analysis of the SwissPrEPared cohort study , Swiss Medical Weekly: Vol. 152 No. 2526 (2022)
Philip Bruggmann, Eliminating viral hepatitis B and C in times of war and increasing global refugee crisis , Swiss Medical Weekly: Vol. 153 No. 4 (2023)
Rainer Fretz, Francesco Negro, Philip Bruggmann, Daniel Lavanchy, Andrea De Gottardi, Isabelle Pache, Virginie Masserey Spicher, Andreas Cerny, Hepatitis B and C in Switzerland – healthcare provider initiated testing for chronic hepatitis B and C infection , Swiss Medical Weekly: Vol. 143 No. 1920 (2013)
Helen Guggisberg, Dunja Nicca, Anton Kohler, Philip Bruggmann, Patrizia Künzler-Heule, “Shaping the new freedom”: A reflexive thematic analysis on patients’ post cure needs after years of living with hepatitis C , Swiss Medical Weekly: Vol. 152 No. 2324 (2022)
Najibulah Gholami, Lukas Boesch, Luis Falcato, Rudolf Stohler, Philip Bruggmann, QTc prolongation in methadone maintenance – the role of HCV infection , Swiss Medical Weekly: Vol. 143 No. 3536 (2013)
Gilles Wandeler, Jean-François Dufour, Philip Bruggmann, Andri Rauch, Hepatitis C: a changing epidemic , Swiss Medical Weekly: Vol. 145 No. 0506 (2015)
Andrea Bregenzer, Philip Bruggmann, Erika Castro, Alberto Moriggia, Madeleine Rothen, Maria Christine Thurnheer, Pietro Vernazza, Claude Scheidegger, Hepatitis C virus elimination in Swiss opioid agonist therapy programmes – the SAMMSU cohort , Swiss Medical Weekly: Vol. 151 No. 0910 (2021)

1 2 > >>

[1] Keiser O, Giudici F, Müllhaupt B, Junker C, Dufour JF, Moradpour D, et al.; Swiss Hepatitis C Cohort Study and the Swiss National Cohort. Trends in hepatitis C-related mortality in Switzerland. J Viral Hepat. 2018;25(2):152–60. doi:.https://doi.org/10.1111/jvh.12803

[2] Schürch S, Fux C, Dehler S, Conen A, Knuchel J, Friedl A, et al. Management of hepatitis C in opioid agonist therapy patients of the Swiss canton Aargau within and outside the cohort study. Swiss Med Wkly. 2020.;150:w20317. doi:. https://doi.org/10.4414/smw.2020.20317

[3] Beck T, Bruggmann P, Haemmig R, Caflisch C, Falcato L, Fink A, et al. Medizinische Empfehlungen für Opioidagonistentherapie (OAT) bei Opioidabhängigkeits-Syndrom 2020. Bern: SSAM; 2020.

[4] Federal Office of Public Health Switzerland. Hepatitis C bei Drogenkonsumierenden. Richtlinien mit settingsspezifischen Factsheets. Bern: 2019. https://www.infodrog.ch/files/content/hepc_de/richtlinien-hepatitis-c-drogen-de-2019.pdf

[5] Kind J, Maeschli B, Bruggmann P. Im Schatten von HIV: Das “Aschenbrödel” Hepatitis C. Suchtmedizin. 2019;21(3):103–10.

[6] Müller D, Dittli J, Eder J, Ettlin E, Janiak C, Stöckli H. Motion 19.3743: Die Eliminierung von Hepatitis gehört in ein Nationales Programm sexuell und blutübertragbarer Infektionskrankheiten. In: EDI, editor. Bern: Die Bundesversammlung - das Schweizer Parlement; 2019.

[7] Hepatitis Schweiz. The HepCare Project: Swiss Hepatitis; 2020: www.hepcare.ch.